Rosetta Biosoftware Licenses the Rosetta Resolver Gene Expression Analysis System to the Functional Genomics Center Zurich
Rosetta Biosoftware announced today that the Functional Genomics Center of Zurich, Switzerland (FGCZ) licensed the Rosetta Resolver system. The FGCZ will use the Resolver system to analyze and store cross-platform microarray data generated from the hundreds of regional functional genomic projects supported by the expert institution.
“Rosetta Biosoftware is pleased to provide the FGCZ with a flexible and integrated informatics solution that will guarantee consistency and quality for their gene expression research,” said Yelena Shevelenko, vice president and general manager of Rosetta Biosoftware. “The Resolver system provides advanced tools for raw and analytical gene expression data management. The cross-species and cross-platform analysis tools in the system will help the FGCZ advance their research in transcriptomics.”
“We are pleased to add the Resolver system to our strong portfolio of analytical resources for conducting genome-wide, high-resolution gene expression analysis. The central database and standardized statistical tools will enable all our users to efficiently analyze microarray data for differential expression,” said Dr. Ralph Schlapbach, managing director of the FGCZ.
The Rosetta Resolver system is developed and supported by Rosetta Biosoftware, and is distributed exclusively by Agilent Technologies.
About the Rosetta Resolver System
The Rosetta Resolver system is a high-capacity data storage, retrieval, and analysis solution for gene expression data. The system is ideal for life science research organizations that need to assess compound specificity or toxicity, identify new genes or therapeutic targets or compare and analyze large databases of expression profiles. The Rosetta Resolver system combines flexibility and ease of use with high-performance algorithms to produce a comprehensive solution for rapid analysis of gene expression data. The Rosetta Resolver system can accept and analyze data from a wide variety of expression profiling formats, including Agilent DNA microarrays, and applies Rosetta Biosoftware’s proprietary error models to yield quality statistics for every gene expression measurement within the system. These statistics are automatically leveraged by Rosetta Resolver system analysis tools for optimal results.
In addition to the FGCZ, life science research organizations that have licensed the Rosetta Resolver system include many of the top pharmaceutical companies in the world, such as Aventis Pharmaceuticals, Bristol-Myers Squibb, GlaxoSmithKline and Merck & Co., Inc., as well as premier academic institutions such as the Harvard University Center for Genomics Research and the California Institute of Technology. Additional information about the Rosetta Resolver system can be found on the Rosetta Biosoftware Web site at www.rosettabio.com .
About Rosetta Biosoftware
Rosetta Biosoftware is a leading provider of informatics solutions for life science research. Its comprehensive software solutions, including the Rosetta Resolver and Rosetta Elucidator systems, empower life scientists with advanced, scalable, and easy-to-use analysis platforms that accelerate discovery research. Rosetta Biosoftware is a business unit of Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co., Inc. (NYSE: MRK). More information about Rosetta Biosoftware is available at www.rosettabio.com .
About FGCZ
The FGCZ is a joint center of excellence of the Swiss Federal Institute of Technology Zurich and the University of Zurich. The FGCZ supports and enables research projects in the area of life sciences by providing state-of-the-art analytical technologies and expertise. In addition, the FGCZ carries out technology and methods development in functional genomics. For further information, please visit www.fgcz.ethz.ch .
Rosetta Resolver and Rosetta Elucidator are U.S. registered trademarks of Rosetta Inpharmatics LLC.
